Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946699 | 0.81 | HSD17B10 (0.56) | KDM4EHSD17B10MEN1KMT2AADRB2 | |
| SCHEMBL15641135 | 0.80 | GABRR1 (0.33) | KDM4EALDH1A1TDP1 | |
| SCHEMBL19969964 | 0.79 | KDM4E (0.46) | KDM4EHSD17B10MEN1KMT2AADRB2 | |
| SCHEMBL3883091 | 0.78 | HTT (0.61) | HTTKDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL13989307 | 0.78 | HTT (0.50) | HTTKDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL1471751 | 0.76 | HTT (0.59) | HTTHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL9928007 | 0.75 | KDM4E (0.42) | HTTKDM4EHSD17B10ADRB2ADRB1 | |
| SCHEMBL13947072 | 0.74 | HSD17B10 (0.52) | HTTKDM4EHSD17B10ADRB2ADRB1 | |
| SCHEMBL11233531 | 0.73 | KDM4E (0.52) | HTTKDM4EHSD17B10TDP1POLB | |
| SCHEMBL710304 | 0.72 | HTT (0.57) | HTTKDM4EHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | HTT 4563/4885KDM4E 3469/4885HSD17B10 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.